Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.
Scientists have developed a novel process that may help personalize anticancer treatments.
Women who experience food or housing insecurity may be at risk for undiagnosed breast cancer due to lapses in follow-up appointments, according to research being presented at the annual meeting of the Radiological Society of North America (RSNA).
Unrelated mutations, when present in the blood, can lead to false positive results in men with advanced prostate cancer who are undergoing liquid biopsies.
The U.S. Food and Drug Administration (FDA) has given final approval to only 4% of all cancer therapeutic drugs being developed.
For many cancers, doctors are increasingly looking to the DNA that solid tumors shed into the blood stream to help with diagnosis and monitoring.
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.
Imaging techniques could replace the need for invasive tissue biopsies in helping rapidly determine whether cancer treatments are working effectively, according to researchers at the University of Cambridge.
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop - and, in many cases, resistant to lifesaving drugs.
Because cancer is easier to successfully treat when it's caught early, a major goal in cancer research is to develop new ways to find tumors at early stages, before they start to spread. One approach that's being studied are liquid biopsies.
Researchers from the Garvan Institute of Medical Research have uncovered four new subtypes of cells within triple-negative breast cancer, which contain promising new therapeutic targets for the aggressive disease.
Enzymes used by bacteria to break down mucus in the gut could provide a useful biomarker for intestinal diseases, according to new research published in Nature Communications.
Brain tumors are typically diagnosed using MRI imaging, as taking a sample for a tissue biopsy is risky and may not be possible due to tumor location or a patient's poor health conditions.
Researchers at the University of Chicago Medicine Comprehensive Cancer Center, working with colleagues in Europe, created a deep learning algorithm that can infer molecular alterations directly from routine histology images across multiple common tumor types.
Cancer diagnosis requires a lengthy process of multiple analyses of tissue biopsies, impeding the quick and early detection of cancers.
A new study has revealed how immune cells migrate to the lymph nodes and help attack harmful viruses and bacteria.
Mount Sinai researchers have pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2) that can distinguish atopic dermatitis (AD) and psoriasis with 100 percent accuracy using adhesive tape strips, a non-invasive alternative to skin biopsy.
Rare inherited mutations in the body's master regulator of the DNA repair system – the TP53 gene – can leave people at a higher risk of developing multiple types of cancer over the course of their lives.
Scientists have created a human cell “membrane on a chip” that enables tracking of the interaction of drugs and infectious agents with the human cells.
Genomic mutation testing is critical to the therapeutic selection and management of patients with colorectal cancer.